[Prevention of thromboembolism in hysterectomies with low molecular weight heparin Fragmin]
- PMID: 2836259
- DOI: 10.1055/s-2008-1035716
[Prevention of thromboembolism in hysterectomies with low molecular weight heparin Fragmin]
Abstract
In comparison to standard heparins, the low-molecular types are said to have equal or better antithrombotic action and--since they affect coagulation less--to induce fewer hemorrhage complications. As they have a longer biologic half-life, a single subcutaneous injection per day is sufficient. In a prospective randomized study patients who had undergone vaginal and abdominal hysterectomy were given either the low-molecular heparin Fragmin (n = 95) or a combination of heparin-dihydergot (n = 98) as prophylaxis against thrombosis. Dosages of Fragmin were 2 X 2500 anti-Xa units on the day of surgery (Day 1) and 1 X 5000 anti-Xa units from Days 2 to 8; the dosage of heparin-dihydergot (HDHE) was 2 X 5000 IU heparin with 0.5 mg DHE from Days 1 to 8. There was no difference between the two groups with regard to the tendency to intraoperative bleeding, the incidence of severe wound hematomas and the postoperative hemoglobin course. Blood quantities in the drains were somewhat higher in the Fragmin group. Hemostasis studies showed that, also in patients on Fragmin, the activated partial thromboblastin time, thrombin time and reaction and clot formation time in the thromboelastogram are significantly prolonged three to four hours after injection. The heparin activity measured as the anti-Xa factor was higher by a factor of ten in patients on Fragmin than in those on HDHE. The thromboserate, recorded thermographically with the DeVeTherm unit, was the same in the two groups. Subjective acceptance of Fragmin prophylaxis was distinctly higher. Further studies to establish the required dose and show the effectiveness of low-molecule heparins seem necessary.
Similar articles
-
[The risk of hemorrhaging in the prevention of thromboembolism in general surgery: comparison of low-dose heparin and heparin-dihydergot 2500].Chirurg. 1983 Jan;54(1):29-32. Chirurg. 1983. PMID: 6851723 Clinical Trial. German.
-
[Prevention of thromboembolism with low molecular weight heparin (Fragmin) in obstetrics].Z Geburtshilfe Perinatol. 1994 Aug;198(4):120-5. Z Geburtshilfe Perinatol. 1994. PMID: 7975797 Clinical Trial. German.
-
[Peroperative thromboembolism prophylaxis: low-dose heparin or low molecular weight heparin-DHE, the advantages and disadvantages. A prospective randomized study].Helv Chir Acta. 1987 Dec;54(4):521-5. Helv Chir Acta. 1987. PMID: 2833477 Clinical Trial. German. No abstract available.
-
[The value of heparin-dihydergot in the prevention of thromboembolic complications].Schweiz Med Wochenschr. 1984 Mar 10;114(10):322-32. Schweiz Med Wochenschr. 1984. PMID: 6369529 Review. German.
-
[Low molecular weight heparins].Pathol Biol (Paris). 1986 Jan;34(1):61-9. Pathol Biol (Paris). 1986. PMID: 3517772 Review. French.
Cited by
-
Low molecular weight heparin in prevention of perioperative thrombosis.BMJ. 1992 Oct 17;305(6859):913-20. doi: 10.1136/bmj.305.6859.913. BMJ. 1992. PMID: 1281030 Free PMC article. Clinical Trial.
-
American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients.Blood Adv. 2019 Dec 10;3(23):3898-3944. doi: 10.1182/bloodadvances.2019000975. Blood Adv. 2019. PMID: 31794602 Free PMC article.
-
Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.Drugs. 1996 Aug;52(2):276-305. doi: 10.2165/00003495-199652020-00011. Drugs. 1996. PMID: 8841743 Review.
-
Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.Drugs. 1990 Oct;40(4):498-530. doi: 10.2165/00003495-199040040-00003. Drugs. 1990. PMID: 1964634 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials